- Home
- BEAT vs CVM Comparison
BEAT vs CVM Comparison
Compare BEAT & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAT | CVM |
|---|---|---|
| Founded | 2015 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 30.1M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BEAT | CVM |
|---|---|---|
| Price | $0.43 | $1.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.63 | N/A |
| AVG Volume (30 Days) | ★ 305.7K | 115.1K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.07 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $315.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.39 | $0.89 |
| 52 Week High | $4.00 | $10.83 |
Technical Indicators
Market Signals| Indicator | BEAT | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 62.41 |
| Support Level | $0.39 | $0.95 |
| Resistance Level | $0.52 | $1.76 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 38.32 | 78.69 |
Price Performance
Historical ComparisonAbout BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.